BioDelivery Sciences developed BUNAVAIL® (Buprenorphine/Naloxone buccal film) for the treatment of opioid addiction. Previously referred to as BEMA® bup/nx, Bunavail uses BDSI's proprietary BioErodible MucoAdhesive (BEMA) delivery technology, also called a buccal film, which adheres to the inside of the cheek. Bunavail has double the bioavailability of Suboxone Film (and generics) and as a result only half the buprenorphine is required per dose. The lower dose may reduce side effects, such as constipation. Bunavail was FDA approved June 6th 2014 and reached pharmacies in November 2014. Bunavail also has less naloxone than competitors with a (6-7):1 ratio compared with the 4:1 (4 parts buprenorphine to 1 part naloxone) found in other offerings.
Bunavail offers a discount plan see NAABT's cost savings page for up-to-date info on cost savings.
To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -